---
source_image: "deposition-transcript+scanned-document+court-document+legal-filing__EFTA01377748_20260130_p001_i001.png"
source_pdf: "EFTA01377748.pdf"
method: pdf_text
words: 735
confidence: 1.00
extracted: 2026-02-13T16:53:53.919649
---

S- I/A 
serving on our board of directors or compensation committee. Ms. Meeker, a General Partner of Kleiner Perkins Caufield & Byers, 
and Mr. Botha. a Managing Member of Sequoia Capital, comprise our compensation committee. Entities affiliated with Kleiner 
Perkins Caufield & Byers and entities affiliated with Sequoia Capital are each parties to our amended and restated investors' rights 
agreement, our amended and restated right of first refusal and co-sale agreement, and our amended and restated voting 
agreement. See the section titled "Certain Relationships, Related Party and Other Transactions' for additional information regarding 
these agreements. 
Director Compensation 
Our non-employee directors did not receive cash or equity compensation for their service on our board of directors and 
committees of our board of directors. As of December 31, 2014. none of our non-employee directors held any outstanding equity 
awards to purchase shares of our common stock, other than Messrs. McKelvey and Viniar and Dr. Summers as described below. 
In 2014, Mr. McKelvey received $39,583 for consulting services provided by him under the terms of a consulting agreement 
with us. 
On June 9, 2011, Dr. Summers was granted an option to purchase 1,288,000 shares of our common stock, which he early 
exercised for restricted shares of our common stock that were subject to the same vesting schedule as the option. One forty-eighth 
of the shares vested on July 9, 2011, and one forty-eighth of the shares vest monthly thereafter, subject to Dr. Summers' 
continued service with us. As of December 31, 2014, Dr. Summers held 161,000 restricted shares of our common stock. 
On October 30, 2013, Mr. Viniar was granted an option to purchase 326,950 shares of our common stock. This option is 
early exercisable. One-fourth of the shares subject to the option vested on October 30, 2014, and one forty-eighth of the shares 
vest monthly thereafter, subject to Mr. Viniar's continued service with us. An additional 12 months of shares subject to the option 
will vest in the event of a change of control of our company if Mr. Viniar remains in service with us at the time of such change of 
control. As of December 31, 2014, Mr. Viniar held an option to purchase 326,950 shares of our common stock. 
On July 9, 2015, Mr. Johnson was granted an option to purchase 38,000 shares of our common stock, which he early 
exercised for restricted shares of our common stock that were subject to the same vesting schedule as the option. All of the shares 
vest on January 1, 2016, subject to Mr. Johnson's continued service with us. 
On August 11, 2015, Dr. Simmons was granted an option to purchase 38,000 shares of our common stock. This option is 
early exercisable. All of the shares subject to the option vest on February 4, 2016, subject to Dr. Simmons' continued service with 
us. 
On October 21, 2015, Mr. Viniar was granted 35,000 RSUs to be settled in shares of our common stock. One-fourth of the 
RSUs vest on the date of our next annual meeting of our stockholders, and one-fourth of the RSUs vest annually thereafter on the 
earlier of the date of the following annual meeting of our stockholders or the anniversary of the prior annual meeting of our 
stockholders, subject to Mr. Viniar's continued service with us. 
155 
Table of Contentr, 
Directors who are also our employees receive no additional compensation for their service as directors. During 2014, 
Mr. Dorsey was our only employee director. See the section titled "Executive Compensation" for additional information about 
Mr. Dorsey's compensation. 
Our compensation committee. after reviewing data provided by our independent compensation consulting firm, Compensia, 
Inc., regarding practices at comparable companies, approved a new compensation policy for our non-employee directors, effective 
January 1, 2016, subject to the effectiveness of the registration statement of which this prospectus forms a part. This non-
employee director policy provides for the following cash compensation to our non-employee directors: 
each non-employee director will receive an annual base retainer of $40,000; 
the chairman of our audit and risk committee will receive an annual fee of $20,000. and other members of our audit and 
risk committee will receive an annual fee of 510,000: 
the chairman of our compensation committee will receive an annual fee of $15,000, and other members of our 
http://www. sec. gov/A rehi vestedgar/data/1512673AMS 1119312515369092/d937622ds I a. htm[ 11/6/2015 7:37:12 AM] 
CONFIDENTIAL - PURSUANT TO FED. R. GRIM. P. 6(e) 
CONFIDENTIAL 
DB-SDNY-0074900 
SDNY_GM_00221084 
EFTA01377748
